ProQR Therapeutics N.V.
NASDAQ:PRQRBiotechnology
+$0.21 today
- Market cap
- $155.23M
- Beta
- 0.06
- P/E (TTM)
- -3.8
- EPS (TTM)
- -$0.43
Volume 0.88M
Average 0.62M
PRQR Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
ProQR Therapeutics N.V.NASDAQ: PRQR
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses dips below year-ago levels
Q1 FY2026 operating expenses of €15.23M fell 0.7% year over year, behind the +12.1% change in trailing-twelve-month operating expenses. Sequentially, it rose 17.1% from the prior quarter. Over 3 fiscal years it compounded at -7.3% a year.
Context
- Operating expenses amounted to 358.9% of revenue in FY2025, up 97.7 pp from a year earlier.
- Operating expenses increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -0.7% toward the trailing-twelve-month pace of +12.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
EUR · from the income statement
- Latest · FY2025
- 54.84M EUR
- Year-over-year change
- +11.1%
- 4-year CAGR
- -1.6%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 54.84M | +11.1% |
| FY2024 | 2024-12-31 | 49.38M | +28.7% |
| FY2023 | 2023-12-31 | 38.37M | -44.2% |
| FY2022 | 2022-12-31 | 68.75M | +17.4% |
| FY2021 | 2021-12-31 | 58.55M | — |
Operating Expenses vs competitors
How PRQR compares with its peers on the latest reported figures
- Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +12.1% is the 6th highest of 11, against a peer median of -0.2%.
- Operating expenses amounts to 435.3% of revenue for PRQR, versus a peer median of 846.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $361.73M USD | +36.9% | +16.5% | 166.1% | |
| LTM Mar 2026 | $144.1M USD | -14.3% | +22.2% | 2511.3% | |
| LTM Mar 2026 | $130.57M USD | -39.9% | -10.4% | 287.9% | |
| LTM Mar 2026 | $117.37M USD | -46.1% | -16.4% | 303.3% | |
| LTM Mar 2026 | $112.97M USD | -32.5% | -15.4% | — | |
ZURAZura Bio Limited | LTM Mar 2026 | $81.49M USD | +23.4% | +40.4% | — |
| LTM Mar 2026 | $77.53M USD | +359.8% | +118.0% | — | |
| FY2025 | A$70.06M AUD | +39.0% | +29.1% | 1388.9% | |
| LTM Mar 2026 | €58.51M EUR | +12.1% | -7.3% | 435.3% | |
| LTM Mar 2026 | $52.34M USD | +13.8% | +10.2% | — | |
| LTM Mar 2026 | $37.72M USD | -21.8% | -10.5% | 7543.6% | |
| Peer median (excluding PRQR) | — | -0.2% | +13.4% | 846.1% | |
Competitors are the stored peer set for PRQR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.34M | 3.59M | 6.51M | 18.91M | 15.28M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 2.6M |
| Gross Profit | 1.34M | 3.59M | 6.51M | 18.91M | 12.68M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 83.0% |
| Research & Development | 42.22M | 50.87M | 25.15M | 36.36M | 40.72M |
| Selling, General & Admin | 17.37M | 18.65M | 16.24M | 13.66M | 14.12M |
| Operating Expenses | 58.55M | 68.75M | 38.37M | 49.38M | 54.84M |
| Depreciation & Amortization | 2.33M | 2.52M | 2.51M | 2.76M | 2.6M |
| EBITDA | (54.95M) | (56.46M) | (24.1M) | (24.12M) | (37.04M) |
| EBITDA Margin | -4116.0% | -1571.0% | -369.9% | -127.6% | -242.4% |
| Operating Income | (57.21M) | (65.16M) | (31.86M) | (30.47M) | (42.15M) |
| Operating Margin | -4285.4% | -1813.0% | -489.1% | -161.2% | -275.9% |
| Interest Income | 5K | 106K | 2.59M | 3.25M | 2.24M |
| Interest Expense | 3.41M | 5.13M | 1.2M | 1.08M | 866.4K |
| Other Income / Expenses | (3.47M) | 1.05M | 4.05M | 2.51M | 1.65M |
| Income Before Tax | (60.68M) | (64.11M) | (27.81M) | (27.96M) | (40.5M) |
| Pre-Tax Margin | -4545.5% | -1783.8% | -427.0% | -147.9% | -265.1% |
| Income Tax Expense | 117K | 96K | (78K) | (197K) | 18.25K |
| Net Income | (60.74M) | (64.42M) | (28.12M) | (27.76M) | (40.52M) |
| Net Margin | -4549.8% | -1792.5% | -431.7% | -146.9% | -265.2% |
| EPS (Basic) | (0.96) | (0.91) | (0.35) | (0.34) | (0.38) |
| EPS (Diluted) | (0.96) | (0.91) | (0.35) | (0.34) | (0.38) |
| Weighted Avg Shares | 64.18M | 71.64M | 81.01M | 81.67M | 105.33M |
| Weighted Avg Shares (Diluted) | 64.18M | 71.64M | 81.01M | 81.67M | 105.33M |
ProQR Therapeutics N.V.
NASDAQ:PRQR
Intrinsic Alpha fair value
Locked
Current Price
$1.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.